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Background: Although right middle lobe (RML)-atelectasis of the lungs is a common complication of
asthma, the relevant data is limited. The aim of this study is to deﬁne the characteristics of RML atel-
ectasis in asthma during childhood.
Methods: Children with asthma who had recently developed RML atelectasis were included; anti-
inﬂammatory medications, clarithromycin, and inhaled salbutamol were prescribed, chest-
physiotherapy (starting on the sixth day) was applied. Patients were reevaluated on the sixth, four-
teenth, thirtieth, and ninetieth days, chest X-rays were taken if the atelectasis had not resolved at the
time of the previous visit.
Results: Twenty-seven patients (6.8 (4.8e8.3) years, 48.1% male) with RML atelectasis were included.
Symptoms started 15 (7e30) days before admission. The thickness of the atelectasis was 11.8 ± 5.8 mm;
FEV1% was 75.9 ± 14.2 and Childhood Asthma Control Test scores were 11.8 ± 5.6 at the time of
admission. The atelectasis had been resolved by the sixth (n ¼ 3), fourteenth (n ¼ 9), thirtieth (n ¼ 10),
and ninetieth days (n ¼ 3). The treatment response of the patients whose atelectasis resolved in fourteen
days was better on the sixth-day (atelectasis thickness: 4.7 ± 1.7 vs. 11.9 ± 7.3 mm, p ¼ 0.021) compared
to those whose atelectasis resolved later. Nearly half (54.5%) of the patients whose atelectasis had
resolved by fourteen days were using controller medications at the time of admission. However, only two
patients (13.3%) were on controller treatment in the latter group (p ¼ 0.032). Regression analysis didn't
reveal any prognostic factors for the early resolution of atelectasis.
Conclusions: Early diagnosis and treatment of RML atelectasis prevents complications. Patients who had
early resolution of atelectasis had already been on anti-inﬂammatory medications, and responded better
to aggressive treatment within the ﬁrst week.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atelectasis is deﬁned as the incomplete expansion of the lung
parenchyma, leading to alveolar hypoxia and pulmonary vasocon-
striction to prevent ventilation-perfusion mismatching. Children,
especially younger children, are more prone to develop atelectasis
due to smaller and more collapsible airways, more pliant chest
walls, and inefﬁcient collateral ventilation through intra-alveolar
and bronchiole-alveolar pores.1 This predisposition is especially
notable in patients not only with lung diseases2,3 (e.g., pneumonia,.
ety of Allergology.
rgology. Production and hosting by Elseasthma, or cystic ﬁbrosis) but also with systemic diseases4 (e.g.
neuromuscular diseases).
Although segmental or lobar collapse of the lungs is a common
complication of asthma, data about its exact incidence is limited.
The incidence has been recorded in 1.62 percent of the general
population of childrenwith asthma2 and 11 percent and 36 percent
of populations of children with non-hypoxemic and hypoxemic
asthma exacerbations, respectively.5While right middle lobe (RML)
atelectasis is typically seen, sometimes the lingula is involved.6 The
presence of bronchial inﬂammation that produces cellular debris,
mucus plugs, and edema contributes to the development of atel-
ectasis in asthma.
RML atelectasis can resolve spontaneously, but in some cases
the region undergoes atelectasis after acute exacerbation prevents
the lobe from re-expanding; in these cases the lobe remainsvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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the involved lobe may lead to parenchymal damage and bronchi-
ectasis.7 Prompt diagnosis and treatment is mandatory for a better
pulmonary outcome. The term ‘RML syndrome’ is used if the RML
atelectasis is persistent (with a duration longer than one month)
and/or recurrent (2 episodes).7,8 Although there have been some
studies on RML syndrome, little is known about RML atelectasis
regarding its response to treatment and the recovery from RML
syndrome in childhood asthma. Our aim in this follow-up study
was to identify the characteristics and prognostic factors of RML
atelectasis in asthma during childhood.
Methods
Study population
In this prospective study, children between the ages of 3e18
years with an initial diagnosis of asthma who had developed RML
atelectasis during follow-up (Fig. 1) were enrolled from the
outpatient allergy clinic of the Ankara Education and Research
Hospital. The initial diagnosis of asthma was established if there
had been a history of respiratory symptoms, such as intermittent
wheezing, shortness of breath, coughing, and/or reversible expi-
ratory airﬂow limitation, deﬁned by at least a twelve percent
improvement in forced expiratory volume in 1 s (FEV1) following
bronchodilator administration.9 As part of a routine clinical prac-
tice, before making an initial diagnosis of asthma the patients who
participated in this study had been evaluated for the other etiol-
ogies of recurrent respiratory symptomswith other diagnostic tools
including chest X-rays and none of them had been found to have
any structural pulmonary abnormalities at that time. In this study
the chest X-rays revealing atelectasis during follow-up had been
required either due to symptoms where we suspected uncontrolled
asthma or due to the existence of an exacerbation. In that case, the
diagnosis of RML atelectasis was based on radiologic ﬁndings, more
apparent in the lateral view of a chest X-ray as a wedge-shaped,
increased density between the minor and major ﬁssures, with the
apex at the hilum and the base towards the pleura10 (Fig. 1). Pa-
tients were excluded from the study if they had severe, predeﬁned
chronic illnesses other than asthma, including cystic ﬁbrosis, pri-
mary ciliary dyskinesia, chest wall defects.
A survey was administered to each participant regarding de-
mographic characteristics (age, gender, family history for atopic
diseases, and smoke exposure), asthma control parameters (asthma
exacerbations, package of salbutamol consumption, and hospitali-
zations due to asthmawithin the last year), and symptomatology ofFig. 1. Posteroanterior and lateral radiographs of ﬁve-ythe most recent episode (the onset of symptoms before admission,
and the frequency of daytime and nighttime symptoms within the
last month).
The children and their parents also ﬁlled in the Turkish-
language version of the Childhood Asthma Control Test (C-ACT).11
The C-ACT is a self-administered questionnaire with seven items
that assesses asthma symptoms during the day and night, the ef-
fects of asthma on daily life, and the use of rescue medications in
the preceding four weeks.12 A C-ACT score of 19 or lower indicated
inadequately controlled asthma.11 Asthma severity was assessed
according to the type of controller medications used by the pa-
tients, such as inhaled corticosteroids and/or montelukast at the
enrollment visit.9
Study measurements
Spirometry using the ZAN100 spirometry system (nSpire Health,
Longmont, Colorado, USA), complete blood cell count, and immu-
noglobulin E measurements (Uni-Cap; Pharmacia, Kalamazoo,
Michigan, USA) were done with standard procedures. Skin prick
testing (Stallergenes; Antony, France) with twenty-four aero-
allergens, including house dust mites; cockroaches; grass, weed,
and tree pollens; molds; and cat and dog dander was performed
with positive and negative controls. Reactions with an induration of
3 mm or greater than that of the negative control was considered
positive, and childrenwith at least one positive test were diagnosed
as atopic.
In cases where RML atelectasis was diagnosed during the initial
visit, therapy was planned as systemic methylprednisolone (2 mg/
kg/day, for ﬁve days), clarithromycin for probable underlying
infection (20 mg/kg/day, for ten days) and inhaled salbutamol as
needed. On the sixth day of treatment, chest physiotherapy13 was
started and continued until the improvement of atelectasis. For the
purpose of chest physiotherapy13 the patients and their parents
were advised to perform percussion and vibration techniques and
the exercises of deep breathing and coughing about which they
were educated. The medications of the ones who had been already
on regular controller treatment was stepped up according to the
allowed medications and doses implicated according to age in
current GINA guidelines.9 For the ones newly starting to the regular
treatment (either montelukast or low dose inhaled corticosteroids)
the controller medicationwas chosen according to the patient's age
and using capability and started after discussionwith the parents of
the patients and the patient him/herself. The prescriptions were
also given age appropriately in accordance with the GINA
guidelines.9ear-old child with atelectasis of right middle lobe.
Table 1
Demographic characteristics of the study participants (n ¼ 27).
Age (year) 6.8 (4.8e8.3)y
Gender (male) (%) 48.1
Age at diagnosis (year) 6 (4e8)y
Family history for atopic diseases (%) 48.1
Smoke exposure (%) 25.9
Allergic rhinitis (%) 11.1
Atopy (%) 44.4
Asthma exacerbations/last year 3 (2e6)y
Hospitalization/last year (1) (%) 70.4
Salbutamol consumption, box/last year (n ¼ 14) 3 (1.8e4.5)y
Childhood Asthma Control Test score 11.8 ± 5.6z
Asthma severity (%)
Mild intermittent e
Mild persistent 37
Moderate persistent 51.9
Severe persistent 11.1
Symptom onset before admission (day) 15 (7e30)y
Daytime symptom/last month (day) 18.1 ± 11.5z
Nighttime symptom/last month (day) 15.9 ± 11.7z
Controller medications
Inhaled corticosteroids 2
Montelukast 3
Inhaled corticosteroids þ montelukast 2
Inhaled corticosteroids þ long-acting beta agonist 1
y Median (interquartile range).
z Mean ± standard deviation.
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ninetieth days following admittance, and chest X-rays were taken if
the atelectasis had not resolved in the previous visit. Chest X-rays
were performed in twoprojections: posteroanterior and right lateral.
Chest X-rayswere reviewedby the radiologist (CS),whowasblind
to clinical symptoms and ﬁndings. Since no standardized validated
methods to measure the degree of atelectasis on chest X-rays has
been reported until now,14 the radiologist preferred to measure the
maximum thickness of atelectasis on lateral chest X-rays that was
noted in millimeters which is a frequently used method in order to
follow-up the resolution of atelectasis in our tertiary hospital.
Our study was completed in accordance with the ethical stan-
dards speciﬁed in the Declaration of Helsinki, and was approved by
the Medical Ethics Committee of Ankara Education and Research
Hospital. All parents and older children provided informed consent.
Statistical analyses
Statistical analyses were performed by using the SPSS 15 pack-
age programme (SPSS, Inc., Chicago, Illinois, USA). The Kolmogor-
oveSmirnov test was used to categorize continuous variables asFig. 2. Symptoms at thebeing normally or non-normally distributed. Categorical variables
were expressed as frequencies and numerical variables, as mean
(±SD) or median (interquartile range) according to normal or non-
normal distribution, respectively. Differences between the groups
were compared by chi-square, Student's t, or KruskaleWallis tests
according to the distribution of data. Variables with a p value of less
than 0.25 in univariate analysis were examined in the multivariate
logistic regressionmodels. Multivariate logistic regression tomodel
the odds of ‘resolution of atelectasis’ versus ‘persistence of atelec-
tasis’ on day 14 was used with a backward likelihood ratio
modeling strategy. The size of the effect of each of the risk factors
wasmeasured using the odds ratios (OR) and 95 percent conﬁdence
intervals (CI). A p value < 0.05 was considered statistically
signiﬁcant.Results
Twenty-seven children with asthma and RML atelectasis (6.8
(4.8e8.3) years, male 48.1 percent) were included in the study.
None of our patients were older than twelve years of age. Atopywas
determined in twelve (44.4 percent) patients. Over the course of
the last year, patients had experienced frequent asthma attacks
[n ¼ 3 (2e6)] and nineteen children had been hospitalized at least
once due to asthma exacerbation. Eight (28.6 percent) of the pa-
tients were already using controller medications. The characteris-
tics of the subjects are summarized in Table 1.
In the current visit, the onset of asthma symptoms was 15
(7e30) days before admission. The most common presenting
symptoms were coughing (100 percent), sputum production (85.2
percent), dyspnea (70.4 percent) (Fig. 2). Additionally nine patients
(33.3%) had fever at the time of recognition of RML atelectasis.
Physical examination revealed pathologic ﬁndings in 26 (92.6
percent) children with asthma, including rales (11.1 percent),
rhonchi (88.9 percent), wheezing (40.7 percent), and retraction
(25.9 percent). Half of the patients were able to perform lung
function tests, and FEV1 were 75.9 ± 14.2 percent of the predicted
(Table 2). On the chest X-rays, the mean (±SD) of RML atelectasis
was 11.8 ± 5.8 mm at maximum width. As a result, at ﬁrst control
visit; the treatment plans were as follows: inhaled corticosteroids
(ICS) (n ¼ 10), montelukast (n ¼ 1), ICS þ montelukast (n ¼ 6),
ICS þ long-acting beta agonists (LABA) (n ¼ 8), and
ICS þ LABA þ montelukast (n ¼ 2). Statistically, it is impossible to
compare any difference in prognosis between ICS and montelukast
since there was only one patient who used montelukast alone.
However, when we compare patients using inhaled corticosteroidstime of admission.
Table 2
Laboratory ﬁndings of the patients at admission (n ¼ 27).
FEV1% (n ¼ 14) 75.9 ± 14.2y
FVC % (n ¼ 14) 78.1 ± 13.4y
FEF 25e75% (n ¼ 14) 72.8 ± 22.2y
White blood cells 8350 (7325e12,350)z
Eosinophils (%) 1.3 (0.18e3.3)z
Polymorphonuclear leucocytes (%) 62.9 (53.9e81.3)z
Sedimentation 18 (12e27)z
Atelectasis thickness (mm) 11.8 ± 5.8
Ig E (IU/L) 71.0 (31.3e351.8)z
y Mean ± standard deviation.
z Median (interquartile range).
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agonists, there is no difference in terms of prognosis.
As a result of evaluation during the follow-up visits, the reso-
lution of atelectasis had occurred on the sixth, fourteenth, thirtieth,
and ninetieth days in three, nine, ten, and three patients, respec-
tively. Likewise, their C-ACT scores increased (admission:
12.2 ± 5.9; ﬁrst month: 18.9 ± 5.7; second month: 21.5 ± 4.6; third
month: 23 ± 2.4). It is important to note that the median (inter-
quartile range) follow-up period (the period between the initial
diagnosis of asthma and the appearance of atelectasis) of the study
population was 0.66 (0.16e1.3) years and when the follow-up
period of the patients whose atelectasis resolved in 14 days were
compared with the patients whose atelectasis did not resolve in 14
days, no difference was found [0.9 (0.3e1.9) years vs. 0.3 (0.08e0.9)
years, p > 0.05].
The atelectasis did not resolve in two patients, however, they
still had linear atelectasis on the ninetieth day. One of these chil-
dren remained asymptomatic. The other child had undergone high
resolution computerized tomography, which revealed RML atelec-
tasis. His immunological assessment, sweat chloride test, nasal
biopsy for primary ciliary dyskinesia, and tuberculin test were
within normal limits. He was referred to the pediatric pulmonology
department, where he had been treated conservatively. By the end
of one year, he was still symptomatic despite adequate anti-asthma
treatment and developed bronchiectasis.
The ratio of the patients with or without fever at the time of
recognition of atelectasis did not differ in terms of the time period
passed for resolution of atelectasis. However, the treatment
response of the patients whose atelectasis resolved in fourteen days
(n¼ 12) was better on the sixth day (atelectasis thickness: 4.7 ± 1.7
and 11.9 ± 7.3 mm, p ¼ 0.021) compared to the patients whoseTable 3
Features of patients with asthma according to time of resolution of atelectasis.
14 days
(n ¼ 12)
>14 days
(n ¼ 15)
p
Agey (years) 7 (4.5e9.9) 6.8 (5.9e8.1) >0.05
Gender (male) (%) 58.3 42.9 >0.05
Smoke exposure (%) 25 28.6 >0.05
Atopy (%) 41.7 50 >0.05
Exacerbations/last yeary 3.5 (2e4.8) 3 (2e6) >0.05
Hospitalization/last year (%) 66.7 71.4 >0.05
Onset of symptomsy (day) 20 (7e30) 11 (3.5e37.5) >0.05
FEV1%y 83.5 (75e89.5) 76.5 (66.5
e79.5)
>0.05
Controller medication use,
admission (%)
54.5 13.3 0.032
C-ACT, admissionz 11.5 ± 4.8 12.0 ± 6.5 >0.05
C-ACT, month 1z 22.2 ± 3.2 16.8 ± 6.3 0.019
Atelectasis thickness, admissionz 10 ± 1 12.3 ± 7.5 >0.05
Atelectasis thickness, (day 6)z 4.7 ± 1.7 11.9 ± 7.3 0.021
y Median (interquartile range).
z Mean ± standard deviation.atelectasis resolved later in terms of thickness of the atelectasis.
Nearly half of the patients (54.5%) whose atelectasis had resolved in
fourteen days were using controller medications for asthma at the
time of admission. But only two patients (13.3 percent), however,
were on controller treatment in the group of patients whose atel-
ectasis had resolved later than fourteen days (p¼ 0.032). The C-ACT
scores of the patients whose atelectasis resolved in fourteen days
were higher on the thirtieth day compared to the latter group
[22.2 ± 3.2 vs. 16.8 ± 6.3, p¼ 0.019 ] (Table 3). The time to resolution
of atelectasis did not differ in between the patient groups whowere
evaluated either due to uncontrolled asthma or existence of an
exacerbation. Logistic regression analysis for recovery of atelectasis
later than fourteen days did not reveal any prognostic factors,
including asthma control parameters, level of asthma control
(‘uncontrolled’ versus ‘partially controlled’), atopy, serum IgE levels,
or thickness of atelectasis upon admission.
Discussion
In this study, we addressed an issue that for a long time has been
related to complications of uncontrolled asthma. We showed that
most of the study participants' atelectasis (nearly 90 percent) had
resolved at the end of threemonths by appropriate treatment. Most
of the patients who demonstrated early resolution of atelectasis
had already been on anti-inﬂammatory medications, and they
responded better to aggressive treatment within the ﬁrst week.
The right middle lobe is themost commonly involved part of the
lung to develop atelectasis in children with asthma. The unique
anatomic features of the RML (which has a narrow and long lobar
bronchus that starts after a sharp angle from the bronchus inter-
medius) and the relative anatomic conﬁnement of the RML (which
results in poor collateral ventilation) both contribute to the
obstruction of the RML.15,16 Recurrent exacerbations of asthma due
to a worsening of the underlying inﬂammation and/or repeated
episodes of infection further contribute to inadequate clearance of
secretions and the formation of mucus plugs.17 In this study, the
patients represented a population composed of individuals with
uncontrolled asthma who had experienced frequent asthma
symptoms and therefore used bronchodilators regularly. Further-
more, 70 percent of them had been hospitalized due to an asthma
exacerbation within the last year, pointing to the severity of their
symptoms.
For the last decade, the treatment of asthma has principally
focused on the control of parameters, including daytime or night-
time symptoms, the need for bronchodilator use for relief of
symptoms, and activity limitation due to asthma.9,18 Risk factors for
poor asthma outcomes have been published recently, including
excessive bronchodilator use, inadequate ICS use, smoke exposure,
low baseline FEV1, sputum or blood eosinophilia, intensive care
admission, or the occurrence of one or more severe exacerbations
in the previous twelve months.9 Interestingly, complications of
asthma such as pneumothorax, pneumomediastinum, or lobar
atelectasis have not drawn attention and have not been referred to
in the literature. If these complications are not diagnosed and
treated properly, the consequences can be hazardous.
Chest radiography is not routinely recommended for the diag-
nosis of asthma; instead it helps to recognize complications or to
exclude chronic infections and anatomic abnormalities, especially
during childhood.19,20 Typical ﬁndings of an asthmatic lung on
chest X-rays are hyperinﬂation due to intrinsic positive end-
expiratory pressure, paucity of vascular markings in the upper
zones of the lung, and thickened bronchial walls and peribronchial
tissues.20 The threshold for ordering a chest X-ray is high for phy-
sicians today because of a fear of side effects from radiation, and the
difﬁculty of convincing parents (even those whose children have
O. Soyer et al. / Allergology International 65 (2016) 253e258 257persistent respiratory symptoms) of the need for such X-rays. With
the invention of newer techniques such as positron emission to-
mography or magnetic resonance imaging, however, the role of
imaging in the diagnosis and management of asthma has
increased.21
A precise diagnosis of the underlying pathology is essential for
proper treatment of symptoms, especially in cases of atelectasis,
where no single therapy is likely to be successful in all forms.
Evidence-based studies on the management of lobar atelectasis are
lacking.22We treated our patients with systemic corticosteroids not
only for persistent or recurrent asthma symptoms, but also for
atelectasis. Corticosteroids are the cornerstones of asthma treat-
ment, as they reduce the number of inﬂammatory cells in the air-
ways, block neutrophil adherence, and decrease microvascular
leakage; they are also highly effective in inhibiting mucus hyper-
secretion by suppressing the underlying inﬂammation. In addition,
they inhibit the synthesis of arachidonic acid-derived inﬂammatory
mediators like montelukast, which leads to a further decrease in
hyperreactivity.23e26 On the sixth day of the treatment, atelectasis
improved or had undergone resolution in thirteen patients in this
study, whichmay be due to the rapid and potent anti-inﬂammatory
actions of corticosteroids and montelukast.
We used clarithromycin (used for probable underlying infec-
tion) for the management of atelectasis, whether or not the patient
had fever. There is an association of RML collapse with bacterial
infections in children with asthma27 and bronchoalveolar lavage
cultures of patients with RML atelectasis revealed the presence of
Haemophilus inﬂuenzae, Streptococcus pneumonia, and Staphylo-
coccus aureus.27,28 Macrolides exhibit not only antimicrobial fea-
tures29 but also immunomodulatory actions, such as the inhibition
of pro-inﬂammatory transcription factors, goblet cell hyperplasia
and the reduction of airway interleukin-8 and neutrophil
numbers.30e32 Nevertheless, placebo controlled trials are needed to
demonstrate the effectiveness of antibiotics in RML atelectasis.
The basic therapeutic options for asthma rely on the use of
controller and reliever medications. A lack of ICS treatment as a
controller medication is a risk factor for both developing ﬁxed
airﬂow limitation and future exacerbation.9 Additionally one of our
study's important ﬁndings was the rapid improvement of atelec-
tasis in children who had been using controller medications. There
were 8 patients who had been already on controller treatment such
as montelukast and/or ICS with or without LABA at the time of
recognition of RML atelectasis (Table 1). The constant reduction of
inﬂammation of the airways by regular ICS and/or montelukast
intake might contribute to the rapid response and resolution of
atelectasis. Furthermore, glucocorticoid receptor a expression is
down-regulated in vitro by glucocorticoids, but in vivo, down-
regulation of the receptor by glucocorticoids treatment does not
appear to occur.33
A limitation of our study was that we did not determine the
frequency of RML syndrome in childrenwith asthmawho admitted
to our allergy department and who had taken chest X-rays during
the study period; this was beyond our aim. A caseecontrol study
may demonstrate the efﬁcacy of different management protocols.
Another limitation would be the sample size. Further studies
regarding right middle lobe atelectasis with more number of par-
ticipants would be informative since studies on this topic are
relatively scarce in pediatric age group.
In conclusion, treatment with controller medications in known
asthmatics might decrease the severity and speed the resolution of
RML atelectasis, and that in most children the problem might
resolve within 90 days with treatment. Control chest X-rays may be
required after a one-month follow-up to ensure that the atelectasis
is resolved. If there is no recovery, cases should be followed closely
to prevent the development of complications and the need forsurgical interventions. Baseline treatment of asthma with anti-
inﬂammatory medications not only controls asthma symptoms
but also accelerates the resolution of atelectasis.
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